UK bladder cancer market is estimated to grow considerably at a CAGR of around 9.8% during the forecast period. UK has one of the finest healthcare systems in the EU region which enables it to provide quality healthcare to the individual citizens. Numerous factors are affecting the prevalence of bladder cancer in the country, such as the increasing population and exposure to a specific type of chemicals among numerous others. As the lifestyle of the people across the region changes, thereby changing the eating habits, this is expected to increase the prevalence of bladder cancer in the coming years. Smoking is one of the key reasons for the rising prevalence of bladder cancer across the population. The percentage of population smoking in the UK is majorly between the age group of 25-34. Owing to this, the prevalence of bladder cancer is expected to increase, thereby creating opportunities for the growth of the market in the near future.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-bladder-cancer-market
UK bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy.
The companies which are contributing to the growth of the UK bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
UK Bladder Cancer Market Segmentation
By Cancer Type
- Transitional Cell Bladder Cancer/ Urothelial Carcinoma
- Squamous Cell Bladder Cancer
- Adenocarcinoma
- Others (Sarcomas, Carcinoma in Situ)
By Diagnosis
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (IVP)
- Others (Biomarkers)
By Treatment
- Surgery
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others (Targeted Therapy)
A full report of UK Bladder Cancer Market available @ https://www.omrglobal.com/industry-reports/uk-bladder-cancer-market
Company Profiles
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Pfizer Inc.
